INO
Inovio Pharmaceuticals Inc
$
1.440
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.470
Open
1.410
VWAP
1.44
Vol
764.26K
Mkt Cap
73.38M
Low
1.410
Amount
1.10M
EV/EBITDA(TTM)
--
Total Shares
25.91M
EV
3.49M
EV/OCF(TTM)
--
P/S(TTM)
154.33
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
8.33K
-91.73%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Inovio Pharmaceuticals, Inc. (INO) for FY2025, with the revenue forecasts being adjusted by -95.83% over the past three months. During the same period, the stock price has changed by -25.77%.
Revenue Estimates for FY2025
Revise Downward
-95.83%
In Past 3 Month
Stock Price
Go Down
-25.77%
In Past 3 Month
5 Analyst Rating
427.78% Upside
Wall Street analysts forecast INO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INO is 7.60 USD with a low forecast of 3.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
2 Hold
0 Sell
Moderate Buy
427.78% Upside
Current: 1.440
Low
3.00
Averages
7.60
High
13.00
427.78% Upside
Current: 1.440
Low
3.00
Averages
7.60
High
13.00
Piper Sandler
Edward Tenthoff
initiated
$5
2025-07-09
Reason
Piper Sandler
Edward Tenthoff
Price Target
$5
2025-07-09
initiated
Reason
Piper Sandler analyst Edward Tenthoff initiated coverage of Inovio with an Overweight rating and $5 price target. The company is is developing DNA-encoded medicines to treat cancer, infectious and rare diseases, the analyst tells investors in a research note. The firm says INO-3107, being developed to treat recurrent respiratory papillomatosis caused by human papillomavirus, was well tolerated and achieved robust clinical efficacy in a Phase I/II study.
Oppenheimer
Oppenheimer
Outperform
downgrade
$15 -> $13
2025-05-14
Reason
Oppenheimer
Oppenheimer
Price Target
$15 -> $13
2025-05-14
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Inovio to $13 from $15 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 2025 results with $25.1M OpEx and cash balance of $68.4M, which is expected to provide runway into Q1 2026. Encouragingly, Inovio remains on track to initiate rolling BLA submission for INO-3107 in mid-2025, and subsequent filing completion in the second half of 2025 could support potential approval as early as mid-2026 if granted priority review, Oppenheimer adds.
HC Wainwright & Co.
Raghuram Selvaraju
Hold
Reiterates
$3
2025-03-19
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$3
2025-03-19
Reiterates
Hold
Reason
RBC Capital
Gregory Renza
Hold
Maintains
$6 → $5
2025-03-19
Reason
RBC Capital
Gregory Renza
Price Target
$6 → $5
2025-03-19
Maintains
Hold
Reason
RBC Capital lowered the firm's price target on Inovio to $5 from $6 and keeps a Sector Perform rating on the shares. The company continues to drive steady advancement of its diverse pipeline in the background, but attention remains squarely on the RRP opportunity, commercial setup, and Inovio's ability to execute, the analyst tells investors in a research note. RBC adds however that its reduced price target reflects the one-year cash runway for 3107's critical though risky path.
Citizens Capital Markets
Roy Buchanan
Buy
Reiterates
$18
2025-03-14
Reason
Citizens Capital Markets
Roy Buchanan
Price Target
$18
2025-03-14
Reiterates
Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Hold
Maintains
$5 → $3
2025-01-13
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$5 → $3
2025-01-13
Maintains
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Inovio Pharmaceuticals Inc (INO.O) is -0.70, compared to its 5-year average forward P/E of -4.21. For a more detailed relative valuation and DCF analysis to assess Inovio Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.21
Current PE
-0.70
Overvalued PE
0.42
Undervalued PE
-8.85
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.73
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.16
Undervalued EV/EBITDA
-4.62
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
412.96
Current PS
2935.26
Overvalued PS
963.46
Undervalued PS
-137.54
Financials
Annual
Quarterly
FY2025Q1
65.34K
Total Revenue
FY2025Q1
YoY :
-19.89%
-25.05M
Operating Profit
FY2025Q1
YoY :
-35.36%
-19.69M
Net Income after Tax
FY2025Q1
YoY :
-61.07%
-0.51
EPS - Diluted
FY2025Q1
YoY :
-6.47%
-26.93M
Free Cash Flow
FY2025Q1
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+123.25%
-36.28K
FCF Margin - %
FY2025Q1
-30.14K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
2.0
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
1.3M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
INO News & Events
Events Timeline
2025-08-11 (ET)
2025-08-11
08:09:12
Inovio announces peer-reviewed data from INO-3107 study
2025-07-03 (ET)
2025-07-03
07:30:58
Inovio 14.286M share Spot Secondary priced at $1.75
2025-07-02 (ET)
2025-07-02
16:18:52
Inovio announces common stock and warrants offering, no amount given
Sign Up For More Events
Sign Up For More Events
News
9.0
08:05 AMPRnewswirePinnedData Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)
8.0
11:00 AMTipRanksOptions Volatility and Implied Earnings Moves This Week, August 11 – August 14, 2025
9.5
08-04PRnewswireINOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025
Sign Up For More News
People Also Watch
FAQ
What is Inovio Pharmaceuticals Inc (INO) stock price today?
The current price of INO is 1.44 USD — it has increased 2.13 % in the last trading day.
What is Inovio Pharmaceuticals Inc (INO)'s business?
What is the price predicton of INO Stock?
What is Inovio Pharmaceuticals Inc (INO)'s revenue for the last quarter?
What is Inovio Pharmaceuticals Inc (INO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Inovio Pharmaceuticals Inc (INO)'s fundamentals?
How many employees does Inovio Pharmaceuticals Inc (INO). have?